Senseonics’ (SENS) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Senseonics (NASDAQ:SENS) in a research report report published on Tuesday,Benzinga reports. They currently have a $14.00 price objective on the stock. HC Wainwright also issued estimates for Senseonics’ Q4 2026 earnings at ($0.54) EPS, FY2026 earnings at ($2.35) EPS, Q1 2027 earnings at ($0.64) EPS, Q2 2027 earnings at ($0.59) EPS, Q3 2027 earnings at ($0.47) EPS, Q4 2027 earnings at ($0.41) EPS, FY2027 earnings at ($2.13) EPS, FY2028 earnings at ($1.56) EPS, FY2029 earnings at ($1.04) EPS and FY2030 earnings at ($0.48) EPS.

A number of other analysts have also recently issued reports on the stock. Mizuho cut their target price on shares of Senseonics from $20.00 to $18.00 and set an “outperform” rating for the company in a research note on Wednesday, July 15th. TD Cowen reiterated a “buy” rating and issued a $15.00 price target on shares of Senseonics in a research note on Tuesday, October 27th. Raymond James Financial upgraded shares of Senseonics from an “underperform” rating to a “market perform” rating in a research note on Tuesday. Barclays assumed coverage on shares of Senseonics in a report on Wednesday, October 7th. They issued an “equal weight” rating and a $10.00 price target on the stock. Finally, Weiss Ratings upgraded shares of Senseonics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, November 4th. Three research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $14.40.

Senseonics Trading Down 3.6%

Shares of Senseonics stock opened at $10.04 on Tuesday. The business has a fifty day simple moving average of $9.16 and a two-hundred day simple moving average of $7.31. Senseonics has a 1 year low of $4.79 and a 1 year high of $13.98. The company has a quick ratio of 6.40, a current ratio of 5.92 and a debt-to-equity ratio of 0.70.

Senseonics (NASDAQ:SENS) last released its quarterly earnings data on Monday, November 9th. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.01). Senseonics had a negative return on equity of 186.11% and a negative net margin of 204.01%. The company had revenue of $19.56 million for the quarter. On average, research analysts anticipate that Senseonics will post -2.30 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Douglas Roeder bought 13,953 shares of the firm’s stock in a transaction on Wednesday, August 19th. The shares were purchased at an average cost of $8.98 per share, with a total value of $125,297.94. Following the acquisition, the director directly owned 171,191 shares in the company, valued at $1,537,295.18. This represents a 8.87% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of SENS. Integrated Wealth Concepts LLC acquired a new position in Senseonics during the second quarter worth about $36,000. The Manufacturers Life Insurance Company bought a new position in shares of Senseonics in the second quarter worth about $65,000. State of Wyoming acquired a new stake in shares of Senseonics in the 2nd quarter valued at approximately $67,000. Kestra Advisory Services LLC acquired a new stake in shares of Senseonics in the 1st quarter valued at approximately $68,000. Finally, Cetera Investment Advisers acquired a new stake in shares of Senseonics in the 1st quarter valued at approximately $85,000. Institutional investors own 12.36% of the company’s stock.

Recent Senseonics Headlines

Here are a few of the latest headlines about SENS:

• Positive Sentiment: Other analyst headlines cite strong price-appreciation outlooks from Mizuho and Barclays, and a TD Cowen price-target increase. Mizuho forecast Barclays forecast TD Cowen target
• Neutral Sentiment: Analyst opinions are not uniformly bullish: Stifel Nicolaus assigned a Hold rating, while Raymond James upgraded SENS to Market Perform. Stifel rating Raymond James rating
• Negative Sentiment: HC Wainwright lowered estimates for Q4 2026 and Q1–Q2 2027, and reduced its FY2027 forecast to a loss of $2.13 per share from $2.05. These near-term revisions could temper the positive effect of its Buy rating, although it raised its Q3 2027 estimate.

About Senseonics

Senseonics Holdings, Inc. develops continuous glucose monitoring (CGM) technology for people with diabetes. Its Eversense systems use a small sensor implanted under the skin to measure glucose levels, an external wearable transmitter to send readings, and a mobile app to display data and provide alerts. The company’s product line includes implantable CGM systems designed for extended wear, including the Eversense 365 system, which is designed to last up to one year. Unlike many CGM products that use sensors replaced more frequently, Eversense sensors are inserted and removed by a healthcare professional.